← Back to Clinical Trials
Recruiting NCT04160533

NCT04160533 Registry of Arterial Hypertension

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04160533
Status Recruiting
Phase
Sponsor National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Condition Arterial Hypertension
Study Type OBSERVATIONAL
Enrollment 10,400 participants
Start Date 2018-06-01
Primary Completion 2026-12-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 99 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 10,400 participants in total. It began in 2018-06-01 with a primary completion date of 2026-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The problem of the quality of primary health care medical system for patients with arterial hypertension is acute for the investigator's country, as these diseases are the most common and cause the high mortality of the population. The concept of "quality of primary health care medical system" includes its timeliness, accessibility and provision of medical care to the patient at the modern level, which is determined by the degree of performance by doctors of medical and diagnostic measures corresponding current clinical recommendations. The system of cardiovascular desease registries, established in the Federal State Clinical Hospital of the Russian Federation Ministry of Public Health with the automated analysis of data on examination and treatment, in comparison with clinical Recommendations. It makes possibility to identify shortcomings and develop approaches to improving the provision of medical care to patients in real clinical practice. Comparative analysis of the quality of examination and treatment in different samples of patients with cardiovascular desease, observed in 2018-2020, compared with results of previous years will identify ptrends in the provision of medical care to patients with cardiovascular desease.

Eligibility Criteria

Inclusion Criteria: The diagnosis of arterial hypertension - Exclusion Criteria: No diagnosis of arterial hypertension \-

Contact & Investigator

Central Contact

Anna Aksenova, MD

✉ aksenovaannav@gmail.com

📞 +74954146186

Frequently Asked Questions

Who can join the NCT04160533 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Arterial Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04160533 currently recruiting?

Yes, NCT04160533 is actively recruiting participants. Contact the research team at aksenovaannav@gmail.com for enrollment information.

Where is the NCT04160533 trial being conducted?

This trial is being conducted at Moscow, Russia, Engel's, Russia, Engel's, Russia, Kemerovo, Russia and 11 additional locations.

Who is sponsoring the NCT04160533 clinical trial?

NCT04160533 is sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation. The trial plans to enroll 10,400 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology